Memantine HCl Basic information
|
Product Name: |
Memantine HCl |
|
Synonyms: |
MEMANTINE HCL;LABOTEST-BB LT00233220;1,3-Dimethyl-5-aminoadamantane hydrochloride;1,3-DIMETHYLAMINOADAMANTANE HYDROCHLORIDE;1-AMINO-3,5-DIMETHYLADAMANTANE HCL;1-AMINO-3,5-DIMETHYLADAMANTANE HYDROCHLORIDE;1-AMINO-3,4-DIMETHYLADAMANTANE HYDROCHLORIDE;3,5-DIMETHYLAMANTADINE HYDROCHLORIDE |
|
CAS: |
41100-52-1 |
|
MF: |
C12H22ClN |
|
MW: |
215.76 |
|
EINECS: |
255-219-6 |
Memantine HCl Chemical Properties
| Melting point | 292 °C |
| storage temp. | Inert atmosphere,2-8°C |
| solubility | Soluble in Water (up to 20 mg/ml) |
| form | Fine Powder |
| color | White |
| Water Solubility | Soluble in water (100mM) |
| Merck | 14,5806 |
| Stability: | Stable for 1 year from date of purchase as supplied. Solutions in distilled water may be stored at -20°C for up to 2 months. |
Memantine HCl Usage And Synthesis
| Description | Memantine HCl is the HCl form of Memantine. Memantine is a well- known neuroprotective drug used for the treatment of Alzheimer's disease. It is believed to be the first neuroprotective drug that has achieve clinical approval by US FDA as well as European. The development of Alzheimer's disease involves the misfolded mutant proteins such as β-amyloid peptide (Aβ, particularly Aβ1−42). These misfolded mutant protein can increase the NMDA response and further cause severe excitotoxicity. Memantine suppresses this process through acting as the antagonist of the N-methyl-d- aspartate-sensitive glutamate receptor (NMDARs). Memantine is also under investigation as a potential treatment for other kind of neurodegenerative disorders such as HIV-associated dementia, neuropathic pain, glaucoma, depression, Huntington's disease, ALS and movement disorders, among other. |
| Chemical Properties | Crystalline Solid |
| Uses |
Used as an antiparkinsonian and antispasmodic Antiparkinsonian;Dopaminergic agonist Anti Alzheimer's |
MEMANTINE HCL CAS NO.41100-52-1 is a dementia treatment drug developed by the German company Merz. It is a new, low-to-moderate affinity, voltage-dependent, non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. It can block NMDA receptors non-competitively, reduce the excessive excitement of NMDA receptors caused by glutamate, prevent cell apoptosis and improve memory. It is a new generation of drugs to improve cognitive function. In February 2002, the European Patent Medicines Committee (CPMP) approved it for the treatment of patients with moderate and severe Alzheimer's disease. MEMANTINE HCL was launched in Germany in August of the same year and was approved by the U.S. Food and Drug Administration on October 17, 2003 ( FDA) approved for the treatment of patients with moderate to severe Alzheimer's disease. Further research shows that memantine hydrochloride is also effective for patients with mild to moderate Alzheimer's disease. Alzheimer's disease (Alzheimerdisease, AD), also known as senile dementia, is one of the common diseases of the elderly. It is mainly manifested as memory loss and recognition impairment. It is a progressive neurodegenerative disease. Currently, cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine hydrochloride are approved for the treatment of Alzheimer's disease.
Hot Tags: memantine hcl cas no.41100-52-1, China, manufacturers, suppliers, factory, custom, wholesale
